Neurocrine’s hopes for hyperplasia blockbuster a step closer after phase 3 win

Neurocrine Biosciences has a lot riding on its hyperplasia drug crinecerfont, which analysts tout as a potential blockbuster. Plus, the company needs a win after throwing in the towel on a Parkinson’s disease med. Luckily, phase 3 data have delivered the goods.